转移性前列腺癌的新型治疗策略
本文通过系统检索Medline、Embase等数据库(2019-2024年),定性综述了转移性前列腺癌的分子靶向治疗进展。针对DNA修复缺陷、错配修复缺陷及PSMA表达等分子亚型,PARP抑制剂、免疫检查点抑制剂和177Lu-PSMA-617等已显示疗效;未来方向包括T细胞衔接抗体、免疫偶联物及靶向AR共因子、PI3K/AKT、PRC2等策略。结论强调需整合多用途生物标志物的注册试验设计以加速药物开发。
要点
- PARP抑制剂靶向DNA修复缺陷(尤其BRCA2/PALB2双等位基因缺失)的前列腺癌。
- PD-1/PD-L1抑制剂对高突变/错配修复缺陷(MMRd)前列腺癌有效。
- 177Lu-PSMA-617作用于PSMA(叶酸水解酶)表达疾病。
核心结论
- 转移性前列腺癌的标准治疗正在快速演变,需采用整合多用途生物标志物的合理注册试验设计以加速抗癌药物开发。
研究设计与样本
- 纳入标准为报告结果的转移性前列腺癌分子靶点或治疗的1-3期研究;排除非英文文章、综述、荟萃分析、评论、病例报告、重复、非人/临床前研究、方案及缺乏分子靶点的研究。
主要发现
- 靶向治疗已用于晚期前列腺癌特定分子亚型,如PARP抑制剂靶向DNA修复缺陷(尤其BRCA2和PALB2双等位基因缺失)。
- 抗PD-1/PD-L1免疫检查点抑制剂在高突变前列腺癌尤其错配修复缺陷(MMRd)疾病中有效。
- 177Lu-PSMA-617影响表达前列腺特异性膜抗原(叶酸水解酶)的疾病。
- 未来治疗进展包括靶向新细胞表面蛋白的T细胞衔接抗体构建体、免疫偶联物和放射性药物。
- 其他合理策略包括靶向持续AR信号、AR共因子(如P300)、PI3K/AKT信号、PRC2复合蛋白(包括EZH2)及新型合成致死策略。
临床怎么用
- 对转移性前列腺癌进行分子分层以选择靶向治疗,如DNA修复缺陷用PARP抑制剂、MMRd用免疫检查点抑制剂、PSMA表达用177Lu-PSMA-617。
局限性
- 本文为叙述性定性综述,非系统评价或荟萃分析,未提供定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The elucidation of prostate cancer biology and genomics has led to new therapies improving disease outcomes with novel androgen receptor (AR) pathway inhibitors (ARPIs), taxanes, and targeted therapeutics that require disease molecular stratification. METHODS: We are presenting a narrative and qualitative synthesis based on a systematic search. Medline (PubMed) and Embase (OvidSP) were searched (October 1, 2024, covering 2019-2024) using keywords and Medical Subject Headings terms; ClinicalTrials.gov and ASCO/ESMO abstracts were also reviewed. The inclusion criteria were phase 1-3 studies on molecular targets or therapies for metastatic prostate cancer with posted results. The exclusion criteria included non-English articles, reviews, meta-analyses, commentaries, case reports, duplicates, nonhuman/preclinical studies, protocols, and studies lacking molecular targets. KEY FINDINGS AND LIMITATIONS: Targeted therapies have emerged for specific molecular subtypes of advanced prostate cancer. For instance, poly(ADP)-ribose polymerase inhibitors target DNA repair defective prostate cancer (especially BRCA2 and PALB2 biallelic loss). Immune checkpoint inhibitors against PD-1/PD-L1 are effective in hypermutated prostate cancer cases, especially those with mismatch repair defective (MMRd) disease. Additionally, 177Lu-PSMA-617 impacts prostate-specific membrane antigen (folate hydrolase) expressing disease. Several other major therapeutic advances are envisioned in the near future, including targeting novel cell surface proteins with T-cell engager antibody constructs, immunoconjugates, and radiopharmaceuticals. Other rational therapeutic strategies are being pursued, targeting continued AR signalling; AR cofactors, for example, P300; PI3K/AKT signalling; the PRC2 complex protein including EZH2; as well as novel synthetic lethal strategies. CONCLUSIONS AND CLINICAL IMPLICATIONS: A rapidly evolving standard of care is anticipated for metastatic prostate cancer, making it imperative that rational registration trial designs incorporating multipurpose biomarkers to accelerate anticancer drug development are pursued.
引用
- Cimadamore A, Boixareu C, Sharp A, et al. Novel Therapeutic Strategies for Metastatic Prostate Cancer Care. Eur Urol. 2025. PMID: 40685286. doi:10.1016/j.eururo.2025.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。